ADMA Biologics (NASDAQ:ADMA) Shares Gap Down – Should You Sell?

ADMA Biologics Inc (NASDAQ:ADMA)’s stock price gapped down before the market opened on Thursday . The stock had previously closed at $9.63, but opened at $8.98. ADMA Biologics shares last traded at $8.0240, with a volume of 12,613,001 shares traded.

Key ADMA Biologics News

Here are the key news stories impacting ADMA Biologics this week:

• Positive Sentiment: Company issues formal refutation of Culper Research’s allegations, calling the report “unsubstantiated, misleading and inaccurate” and defending ASCENIV’s competitive position and revenue recognition. ADMA refutes short-seller claims
• Positive Sentiment: Market coverage notes a rebound after the company’s rebuttal — headlines and articles report ADMA “gains” as traders react to management’s statements. ADMA gains after refuting claims
• Positive Sentiment: Analysts and media flag market attention including Nasdaq reactions and commentary that the company is actively addressing investor concerns — helpful for short‑term sentiment. Market attention coverage
• Neutral Sentiment: Unusual options activity was reported (large call buying), suggesting speculative positioning that can amplify intraday moves but not fundamental direction. (Options volume reported in market notices.)
• Neutral Sentiment: Context pieces note ADMA is down significantly since its last earnings release, highlighting volatility tied to recent results and expectations — useful for evaluating risk vs. reward. Zacks: stock down since earnings
• Negative Sentiment: Multiple securities‑fraud investigations and investor alerts have been launched by a number of law firms after the short report and the subsequent price decline — this increases legal risk and could pressure the stock. Investor investigations announced
• Negative Sentiment: Short‑seller allegations (including claims of channel stuffing) remain in circulation via reports and investor alerts; third‑party scrutiny prompted steep intraday declines last week and remains a key downside risk. Investor alert on short‑seller report
• Negative Sentiment: Cantor Fitzgerald moved the stock after the short‑report fallout (coverage/ratings action reported), adding analyst pressure on sentiment. Cantor Fitzgerald downgrade

Analysts Set New Price Targets

Several research firms have commented on ADMA. Wall Street Zen upgraded ADMA Biologics from a “hold” rating to a “buy” rating in a research note on Saturday, February 28th. Weiss Ratings reiterated a “hold (c)” rating on shares of ADMA Biologics in a report on Tuesday, December 23rd. Cantor Fitzgerald reissued a “neutral” rating on shares of ADMA Biologics in a research report on Thursday. Finally, Zacks Research upgraded shares of ADMA Biologics from a “hold” rating to a “strong-buy” rating in a report on Monday, March 2nd. Two equities research analysts have rated the stock with a Strong Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat, ADMA Biologics has a consensus rating of “Buy” and an average target price of $32.00.

ADMA Biologics Trading Up 11.6%

The firm has a market cap of $2.20 billion, a price-to-earnings ratio of 15.42 and a beta of 0.51. The company has a debt-to-equity ratio of 0.16, a current ratio of 6.71 and a quick ratio of 3.74. The business has a 50-day moving average of $15.60 and a 200-day moving average of $16.42.

ADMA Biologics (NASDAQ:ADMA) last released its quarterly earnings data on Wednesday, February 25th. The biotechnology company reported $0.20 EPS for the quarter, meeting the consensus estimate of $0.20. ADMA Biologics had a return on equity of 37.52% and a net margin of 28.80%.The company had revenue of $139.16 million during the quarter, compared to the consensus estimate of $139.80 million. During the same quarter in the prior year, the firm posted $0.46 EPS. The firm’s revenue for the quarter was up 18.4% compared to the same quarter last year. Research analysts anticipate that ADMA Biologics Inc will post 0.51 EPS for the current year.

Insiders Place Their Bets

In other news, COO Kaitlin M. Kestenberg-Messina sold 10,096 shares of the business’s stock in a transaction dated Monday, March 9th. The shares were sold at an average price of $15.63, for a total transaction of $157,800.48. Following the transaction, the chief operating officer directly owned 466,600 shares in the company, valued at $7,292,958. The trade was a 2.12% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Steve Elms bought 7,000 shares of the company’s stock in a transaction dated Thursday, March 5th. The stock was purchased at an average cost of $15.67 per share, for a total transaction of $109,690.00. Following the completion of the acquisition, the director owned 2,038,730 shares in the company, valued at $31,946,899.10. This trade represents a 0.34% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Company insiders own 3.50% of the company’s stock.

Hedge Funds Weigh In On ADMA Biologics

A number of hedge funds and other institutional investors have recently bought and sold shares of ADMA. State Street Corp increased its position in ADMA Biologics by 0.3% during the fourth quarter. State Street Corp now owns 13,597,259 shares of the biotechnology company’s stock worth $248,014,000 after buying an additional 35,614 shares during the last quarter. Sachem Head Capital Management LP lifted its position in shares of ADMA Biologics by 27.0% in the fourth quarter. Sachem Head Capital Management LP now owns 11,375,000 shares of the biotechnology company’s stock valued at $207,480,000 after buying an additional 2,415,000 shares during the last quarter. Westfield Capital Management Co. LP lifted its position in shares of ADMA Biologics by 36.9% in the fourth quarter. Westfield Capital Management Co. LP now owns 6,992,907 shares of the biotechnology company’s stock valued at $127,551,000 after buying an additional 1,886,105 shares during the last quarter. Capital Research Global Investors boosted its stake in shares of ADMA Biologics by 104.0% during the 4th quarter. Capital Research Global Investors now owns 6,637,472 shares of the biotechnology company’s stock worth $121,067,000 after acquiring an additional 3,383,559 shares during the period. Finally, Nuveen LLC boosted its stake in shares of ADMA Biologics by 3.5% during the 4th quarter. Nuveen LLC now owns 5,926,390 shares of the biotechnology company’s stock worth $108,097,000 after acquiring an additional 202,245 shares during the period. Institutional investors own 75.68% of the company’s stock.

ADMA Biologics Company Profile

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.